Same peptide, two routes. Where you want it to work determines how you take it.
Bottom line: This is not a which-is-better question. It is a where-is-the-problem question. Gut issues , leaky gut, IBD, NSAID damage, ulcers, reflux , go oral. That is actually how most of the animal research was done (gavage). Tendons, ligaments, joints, muscles go injectable, pinned as close to the injury as you can manage. The split is clean. Some people run both simultaneously: oral in the morning for gut, injection near a shoulder injury in the evening. That is not overkill , it is just matching the route to the target.
| BPC-157: Oral | Injectable | |
|---|---|---|
| Delivery | Oral capsules (enteric-coated) or sublingual liquid. Swallow on empty stomach. | Subcutaneous injection, pinned as close to the injury site as anatomically possible. |
| Mechanism | BPC-157 survives gastric acid , unusually stable for a peptide. Acts locally on gut mucosa, with partial systemic absorption downstream. The gut IS the target. | Same BPC-157. SubQ delivers it into subcutaneous fat near the injury. Local concentration at the target tissue is high. Systemic distribution is secondary. |
| Bioavailability | ~10–20% systemic bioavailability. Caveat: for gut targets, the peptide is 100% at the target before it even tries to absorb. The low bioavailability number only matters if you're trying to reach a non-GI target. | High local bioavailability at the injection site. No GI barrier. Direct uptake into surrounding tissue and bloodstream. |
| Reported dose | 250–500 mcg/day. Some protocols go to 1,000 mcg for serious gut conditions to compensate for absorption. Take on empty stomach. | 250–500 mcg/day. No need to dose up , no GI absorption loss. Inject once or twice daily depending on severity. |
| Best for | Leaky gut, IBD, NSAID-induced gut damage, gastric ulcers, reflux, esophageal damage, post-surgical bowel recovery. | Tendons, ligaments, muscles, joints. Anything anatomically locatable that you can inject near. |
| Frequency | Once daily, empty stomach, with enteric-coated capsules. | 1–2x daily, near the injury. Some protocols run twice-daily in the first 2 weeks, then drop to once daily. |
| Cycle length | 4–8 weeks. Gut conditions may warrant longer at lower doses. | 4–8 weeks. Assess injury status at week 4. Extend to 12 if response is partial. |
| Top side effect | Mild nausea, especially without enteric coating or on a full stomach. GI discomfort is transient and often resolves after week 1. | Injection site redness or small welt (resolves within an hour). Mild nausea is rare with SubQ. |
| Evidence tier | Tier 2 , most Sikiric lab animal studies used intragastric administration. Oral route has the strongest research backing of the two for GI targets. No human oral pharmacokinetic study published. | Tier 2 , musculoskeletal data is predominantly animal. One open-label human knee study (n=12, PMID 33220100). Injection is community-dominant for orthopaedic use. |
| Common format | Enteric-coated capsules, 250–500 mcg each. Quality varies enormously between suppliers. Enteric coating is non-negotiable for gut targets. | 5 mg lyophilised vial. Reconstitute with 2 mL bacteriostatic water (500 mcg per 0.2 mL). 30G, 0.5" insulin syringe. |
| Travel / convenience | Pre-dosed, no needles, no cold chain required short-term. Clear winner for travel. | Vials need refrigeration post-reconstitution. Needles need sharps management. Not carry-on friendly. |
| Approval status | Not FDA-approved. FDA Category 1 since Feb 2026 , compoundable with a prescription in the US. | Not FDA-approved. FDA Category 1 since Feb 2026 , compoundable with a prescription in the US. |
tierA: {"tier":2,"label":"Emerging evidence"}
tierB: {"tier":2,"label":"Emerging evidence"}
summary: Both routes sit on animal research. No head-to-head human RCT comparing oral vs injectable BPC-157 exists. The Sikiric lab in Zagreb has published the bulk of the oral data , and the original gastric studies used intragastric administration (gavage), not injection. Injectable data is stronger for musculoskeletal targets. One small human knee study (n=12, open-label) exists. A 2025 ACG systematic review of 36 studies confirmed GI benefits across IBD, ulcer, and NSAID-injury models.
trials: [{"name":"BPC-157 gastric cytoprotection , intragastric vs systemic","peptide":"a","n":"animal","finding":"Comparable efficacy between intragastric and systemic routes in gastric ulcer models. Oral route reaches target tissue directly.","pmid":"24714678"},{"name":"BPC-157 stability in human gastric juice","peptide":"a","n":"in vitro","finding":"BPC-157 remains native and biologically active in human gastric juice for over 24 hours. Most peptides degrade in minutes. (Sikiric et al., 2024, Inflammopharmacology)","pmid":"38806738"},{"name":"BPC-157 tendon fibroblast GH receptor upregulation","peptide":"b","n":"in vitro","finding":"BPC-157 dose- and time-dependently increased growth hormone receptor expression in Achilles tendon fibroblasts, activating JAK2 downstream.","pmid":"25415472"},{"name":"BPC-157 Achilles tendon transection, rat","peptide":"b","n":"animal","finding":"Faster tendon-to-bone healing and fibroblast outgrowth with BPC-157 vs control after full transection.","pmid":"20698082"},{"name":"Intra-articular BPC-157 for knee pain","peptide":"b","n":"12","finding":"Pain relief reported in 11 of 12 patients at 6 months. Open-label, no control group.","pmid":"33220100"},{"name":"2025 ACG systematic review , GI indications","peptide":"a","n":"36 studies","finding":"Functional and structural improvements confirmed across IBD, ulcer, and NSAID-injury models in the largest review of BPC-157 GI evidence to date.","pmid":null}]
{"applies":true,"name":"The dual-route protocol","intro":"These are not competing options. Some people run oral BPC-157 for a gut target and injectable BPC-157 for a shoulder or knee simultaneously. No interaction concerns , same peptide, different delivery points. This is the protocol for anyone dealing with both a GI condition and a musculoskeletal injury.","phases":[{"name":"Gut (oral)","weeks":"Daily, ongoing","a":"250–500 mcg enteric-coated capsule on empty stomach, AM","b":"N/A , this phase is oral only"},{"name":"Injury (injectable)","weeks":"Weeks 1–8","a":"250–500 mcg SubQ near injury site, daily or twice daily","b":"N/A , same peptide, second route"},{"name":"Off","weeks":"Week 9+","a":"Stop oral. Reassess gut. Resume if symptoms return.","b":"Stop injectable. Reassess injury. Extend if partial response."}],"note":"Running both routes simultaneously is double the peptide dose , start with 250 mcg per route, not 500. Monitor nausea. If well tolerated, scale up in week 2."}
It actually works , and this is what makes BPC-157 unusual. A 2024 Inflammopharmacology review (Sikiric et al.) confirmed it remains native and biologically active in human gastric juice for over 24 hours. Most peptides degrade in minutes. This stability is why oral dosing is a real option, not just a workaround for people who can't inject.
Because for gut targets, the 10–20% systemic bioavailability number is misleading. The peptide hits the GI mucosa directly before it absorbs. For a leaky gut or NSAID-damaged stomach, oral is more efficient than injecting , you'd be routing it the long way around.
You can, but you're trading efficacy for convenience. For musculoskeletal targets, injectable near the injury delivers a meaningfully higher local concentration than oral can. It's not zero effect , BPC-157 has systemic mechanisms , but injection is the superior route for anything you can physically point to.
Yes. The dual-route protocol exists for exactly this situation , a gut condition and a physical injury running concurrently. Start at 250 mcg per route (not 500), monitor for nausea in week one, then scale if tolerated.
The Sikiric lab , which published the majority of BPC-157 research , used intragastric gavage (forced oral dosing) for gut studies. Injectable routes were used for musculoskeletal and systemic studies. The 'oral is less studied' claim is backwards for GI targets.
For gut targets specifically: arguably no, because the peptide is stable in gastric acid anyway. But enteric coating ensures consistent release and protects the capsule contents from manufacturing degradation. For sublingual or buccal use, no coating is needed.
For injuries you can't pin directly, inject into the surrounding subcutaneous tissue as close as anatomy allows. The systemic distribution from SubQ will still reach the target , you lose some of the local concentration advantage, but it's still a better delivery than oral for non-GI musculoskeletal use.
Yes. BPC-157 is WADA-prohibited (S0 , unapproved substance) in and out of competition, regardless of route. If you are subject to anti-doping testing, do not use it.
These statements have not been evaluated by the FDA. This content is for educational purposes only. Consult a healthcare professional before starting any protocol. vialprep sells injection supplies, not compounds.
